El interés en corto de Tyra Biosciences da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Tyra Biosciences. Los datos de interés en corto se actualizan cada dos semanas.

Tyra Biosciences (NASDAQ:TYRA) Bolsa, Informe de interés en corto

Tyra Biosciences

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).

Tyra Biosciences Inc

TYRANNA RESOURCES LTD by Tyranna Resources Ltd.

Tyranna Resources Ltd

Trading Ideas

CHEK

Check-Cap Shares Halted On Circuit Breaker To The Upside, Stock Now Up 272.9%

Check-Cap Shares Resumed Trade

News

Analyst Ratings

LOAR

SRAD

Watching Loar Holdings, Sportradar Group; Shares Spike Higher Amid CNBC Mentions Of The Stocks Under Segment Titled "Small Cap Strategy In 2025"

Rosenblatt analyst Steve Frankel maintained a Buy rating on Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a <a target="_blank" href="https://www.benzinga.com/quote/META/analyst-ratings" rel="noreferrer noopener">price target of $811</a>.
The stock is currently featured among the best ideas for the first half of 2025, reflecting key themes across Rosenblatt&#8217;s research universe.
Meta is in the midst of an impressive and durable artificial intelligence-driven growth renaissance, he says.
Revenues rose 22% in the first nine months of 2024 after growing 16% in 2023 and dipping 1% in 2022.
Also Read: <a href="https://www.benzinga.com/24/12/42560942/instagrams-ad-revenue-could-hit-32-billion-by-2025-driving-metas-growth-report" target="_blank" rel="noreferrer noopener">Instagram&#8217;s Ad Revenue Could Hit $32 Billion by 2025, Driving Meta&#8217;s Growth: Report</a>
The growth is principally advertising, which accounts for 98% of sales, and AI-driven. AI is driving up daily usage on Facebook and Instagram, bolstering reel traction and improving ad efficiency.
Meta uses AI to adjust ad loads better, improve action sequences tied to targeting and executing ads, and help advertisers create and manage campaigns, Rosenblatt explained.
Ad revenue rose 19% in the third quarter of 2024, only 300 bps slower than the 22% growth of the second quarter of 2024, despite an 11.5 percentage point stiffer comparison.
From here, comparisons are steadier, suggesting recent traction can continue.
Frankel estimates 19% revenue growth in the fourth quarter of 2024, within the 12% to 20% guidance. We sustain that growth estimate into 2025.
With this revenue growth, Meta has room to absorb more investment.
The analyst assumes capex would increase 20% in 2025 to $46.6 billion, nearly flat as a percentage of sales. Hea also expects expense growth of 14% in 2025, accelerating from an 11% rise in 2024, and has adjusted EBITDA margins rising 110 bps to 62.6%.
Meta has nearly 3.3 billion people using its family of services daily. Its revenue growth affords more AI investment growth than others, a backdrop allowing AI-driven marketing services to improve more than others. With its business primarily performance marketing, a better marketing mousetrap supports share gains, the analyst says.
One risk is global trade volatility. Out-of-region revenue (mainly China and Asia marketers buying ads in the US) was 7% of Meta ad revenue in 2023 and dropped to 5% in the third quarter of 2024.
One could imagine a trade war generating disruption once President-elect Trump officially takes office. However, it is not clear that Trump wants that. He may be threatening tariffs to seek concessions. In a trade war, Chinese and Asian marketers like Temu and Shein could also react by sourcing more locally, supporting continued marketing.
<h2 class="wp-block-heading">Meta And TikTok</h2>
TikTok could be a hedge.
If the Supreme Court allows the law requiring a TikTok sale or ban to stand, then TikTok&#8217;s fate would rest in Trump&#8217;s hands, and he would have the ability to interpret and enforce legislation or push for new legislation.
His recent statements of support for TikTok suggest that he believes trade concessions from China could be won in return for keeping the app.
Alternatively, a whole-out trade war could result in Trump allowing a TikTok ban to come into effect.
Price Action: META stock is up 2.55% at $600.15 at last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42560428/consumer-finance-watchdog-cracks-down-on-credit-card-sneaky-fees-and-false-promises" target="_blank" rel="noreferrer noopener">Consumer Finance Watchdog Cracks Down on Credit Card Sneaky Fees and False Promises</a></li>
</ul>
Image: Shutterstock

Social Media

Price Target

Reiteration

Meta User Base, AI-Powered Ad Growth Drive Analyst Optimism

AMPS

Altus Power Shares Resume Trade

Check-Cap Shares Halted On Circuit Breaker To The Upside, Stock Now Up 223.7%

Looking into the current session, LendingClub Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) shares are trading at $16.15, after a 1.88% decrease. Over the past month, the stock decreased by 1.16%, but over the past year, it actually increased by 81.26%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1734982208_0.png" alt="Past Year Chart" />

<h3>Comparing LendingClub P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
LendingClub has a better P/E ratio of 35.78 than the aggregate P/E ratio of 34.53 of the Consumer Finance industry. Ideally, one might believe that LendingClub Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1734982208_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

Price Over Earnings Overview: LendingClub

Check-Cap Shares Resume Trade

WIIM

Altus Power shares are trading higher after a report suggesting TPG is in talks to acquire the company.

Altus Power Shares Halted On Circuit Breaker To The Upside, Stock Now Up 13.5%

TPG Is In Talks To Acquire Altus Power

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) started the year with an impressive All-Time High (ATH) of greater than $77,000 in March after the approval of Bitcoin ETFs by the US Security and Exchange Commission (SEC). However, BTC has a penchant for exceeding expectations. It shattered the high from earlier in the year on December 3 when it finally crossed the $100,000 mark and reached over $103,5000. Two weeks later, Bitcoin exceeded $107,000 and now sits at just over $92,000.
There are many reasons for Bitcoin's growth and the burgeoning mainstream acceptance of the coin. Consistent global inflation and low interest rates have encouraged institutional and retail investors to look to BTC as a hedge against inflation. The re-election of <a href="https://www.benzinga.com/topic/donald-trump">Donald J. Trump</a> and the announced resignation of <a href="https://www.benzinga.com/topic/gary-gensler">Gary Gensler </a>as chairman of the SEC have also helped foster optimistic sentiments among investors.
Trump nominated Paul Atkins as Gensler's successor and Atkins has a reputation of supporting cryptocurrencies and creating a more open regulatory environment for digital assets stemming from his tenure as SEC Commissioner between 2002 and 2008.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42656507/bitcoin-price-decisively-back-below-100000-what-is-going-on">Bitcoin Price Decisively Back Below $100,000: What Is Going On?</a>
In November, we spoke with investor and Bitcoin supporter, Tim Draper, who called for <a href="https://www.thestreet.com/crypto/markets/following-microstrategy-5-4-billion-btc-buy-draper-says-his-120k-2024-prediction-could-be-underestimating">$120,000 BTC in 2024.</a> Judging by MicroStrategy's $5.4 billion BTC buy, Draper later said the estimate may be too low.
What do other experts in digital assets have to say about the trajectory of the world's most famous cryptocurrency in the waning days of 2024? And where do they see BTC going in 2025?
We spoke with Grant Cardone of Cardone Capital, Caitlin Long of Custodia Bank, Anthony Scaramucci of Skybridge Capital, Sandeep Nailwal of Polygon and Dean Skurka of WonderFi to get their unique perspectives on the future of BTC.
Grant Cardone, Fund Manager / CEO Cardone Capital, CEO of Cardone Training Technologies, Inc.
Cardone, entrepreneur, real estate mogul and motivational speaker, has taken an avid interest in crypto and recently <a href="https://x.com/grantcardone/status/1865983955767357580?s=42">announced the launch</a> of Cardone Capital Space Coast Bitcoin Fund (Fund 26). In a tweet on X, Cardone said: "Commitments for ~100% of $87.5M fund. Targeting 30% annual returns &amp; 100% return of all capital at 48 months."
When asked in interview about the future of Bitcoin, Cardone said "It is still early in fact because of the amount of adoption by governments, corporations, state treasuries &amp; private business owners; we are still very early."
Cardone added the number of ways it's possible to gain exposure to Bitcoin as another cause for confidence.
"You can gain exposure to Bitcoin by buying it directly, through ETF investments, stocks of companies like MicroStrategy and now in real estate vehicles like we've created at CardoneCapital that uses cash flow to dollar cost average purchase the Bitcoin and spike traditional stable real estate returns."
Caitlin Long, Founder &amp; CEO, Custodia Bank
Long is a vocal advocate of Bitcoin and has been an open critic of Gensler's tenure at the head of the SEC. Custodia Bank faced resistance from federal regulators, and in 2023, the Federal Reserve Board rejected it, citing concerns over the risks in digital assets.
Custodia offers segregated custody accounts for Bitcoin and Long is a true believer in the fundamentals behind BTC. In an interview, she expressed her optimism for BTC.
"I don&#8217;t make price predictions, but for fundamental reasons tied to halvings, Bitcoin has pronounced 4-year cycles – 210,000 blocks at 10-minute average block intervals, to be precise. If the past is prologue, 2025 will be a bull market year. Generally, more ‘up and to the right' movements should be on tap!"
Anthony Scaramucci, Founder &amp; CEO of SkyBridge Capital
Scaramucci is a strong supporter of cryptocurrencies and uses his platform to educate traditional investors on BTC's potential. SkyBridge offers crypto funds including the SkyBridge Bitcoin Fund.
He recently published his latest book, "The Little Book of Bitcoin: What You Need to Know that Wall Street Has Already Figured Out."
Asked where he expects BTC to land by the end of 2024, Scaramucci said, "I see us finishing the year around the $100,000 level. We need to digest this big post-election move and see more concrete plans from the Trump regime on new regulatory frameworks."
Scaramucci's prognostications for 2025 were even more bullish, similar to Tim Draper's predictions.
"I see Bitcoin doubling in 2025 to $200,000. Don&#8217;t underestimate Sen. Cynthia Lummis&#8217; determination to build a Strategic Bitcoin Reserve, which would likely cause a cascading effect with other nation-states and corporations." 
Sandeep Nailwal, Co-Founder Of Polygon
Nailwal is a visionary in the blockchain industry, not only for helping to found the Layer 2 blockchain network, Polygon (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/matic/usd">MATIC</a>) to add speed and reduce costs while using the Ethereum Virtual Machine (EVM), but also for his work shaping the Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) ecosystem, creating tools to make blockchain development easier as well as for his work developing ZK-rollups, sidechain technology and modular frameworks for greater scalability.
Nailwal stands with most leaders in the blockchain space – a stronger BTC is a net win for all parts of Web3.
&#8220;Bitcoin's success is a win for everyone in crypto. It builds trust, brings in more people, and shows the world what decentralized tech can do.
As more users and institutions embrace Bitcoin, it creates a gateway for them to explore the broader blockchain space. That isn't just about Bitcoin thriving – it's about unlocking new ideas, driving innovation, and helping the entire ecosystem grow stronger together.&#8221;
Dean Skurka, President And CEO WonderFi
Skura's work has focused on compliance and accessibility in cryptocurrency, ultimately seeking to bring traditional finance and digital finance closer together.
Skura is optimistic that the changing regulatory landscape in the US will be good news for BTC.
"With the incoming administration in the US, discussions of a National Bitcoin Strategic Reserve, and continued institutional inflows into US Spot Bitcoin ETFs, we expect Bitcoin to continue to gain mainstream adoption, which will only further improve the long-term prospects for Bitcoin. The industry's prospects have never looked brighter, and we look forward to many more milestones in 2025."
 Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42655154/84000-is-bitcoins-worst-case-options-trading-firm-ceo-says">$84,000 Is Bitcoin&#8217;s Worst Case, Options Trading Firm CEO Says</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Regulations

Exclusives

Interview

$BTC

$ETH

$MATIC

MATIC

Exclusive Insights: Founders Of Polygon, SkyBridge, Custodia, WonderFi & Cardone Bullish On BTC in 2025

Check-Cap Shares Halted On Circuit Breaker To The Upside, Stock Now Up 189.8%

Deep-pocketed investors have adopted a bearish approach towards Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMGN usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Amgen. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 10% leaning bullish and 60% bearish. Among these notable options, 6 are puts, totaling $327,012, and 4 are calls, amounting to $381,036.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $135.0 to $310.0 for Amgen during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Amgen options trades today is 108.33 with a total volume of 445.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $135.0 to $310.0 over the last 30 days.
<h3>Amgen Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734981331_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$13.4</td>
<td>$13.2</td>
<td>$13.2</td>
<td>$260.00</td>
<td>$209.8K</td>
<td align="right">127</td>
<td align="right">186</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$11.9</td>
<td>$11.75</td>
<td>$11.9</td>
<td>$250.00</td>
<td>$147.5K</td>
<td align="right">64</td>
<td align="right">124</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/27/24</td>
<td>$18.45</td>
<td>$16.85</td>
<td>$17.6</td>
<td>$245.00</td>
<td>$70.4K</td>
<td align="right">2</td>
<td align="right">40</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$131.25</td>
<td>$126.35</td>
<td>$129.07</td>
<td>$135.00</td>
<td>$64.5K</td>
<td align="right">0</td>
<td align="right">5</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$50.2</td>
<td>$49.75</td>
<td>$50.14</td>
<td>$310.00</td>
<td>$44.9K</td>
<td align="right">159</td>
<td align="right">15</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
<h3>Current Position of Amgen</h3>
<ul>
<li>With a volume of 1,153,448, the price of AMGN is down -0.14% at $263.02. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 43 days.</li>
</ul>
<h3>Professional Analyst Ratings for Amgen</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $293.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on Amgen, which currently sits at a price target of $330. 
&#x2A; An analyst from B of A Securities has revised its rating downward to Underperform, adjusting the price target to $256. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Amgen with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

AMGN

Spotlight on Amgen: Analyzing the Surge in Options Activity

Whales with a lot of money to spend have taken a noticeably bullish stance on Cleanspark.
Looking at options history for Cleanspark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) we detected 50 trades.
If we consider the specifics of each trade, it is accurate to state that 56% of the investors opened trades with bullish expectations and 36% with bearish.
From the overall spotted trades, 15 are puts, for a total amount of $5,835,570 and 35, calls, for a total amount of $2,223,001.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $5.0 and $37.0 for Cleanspark, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Cleanspark's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Cleanspark's significant trades, within a strike price range of $5.0 to $37.0, over the past month.
<h3>Cleanspark 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734981326_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$25.6</td>
<td>$25.4</td>
<td>$25.4</td>
<td>$35.00</td>
<td>$1.4M</td>
<td>2.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$25.3</td>
<td>$25.1</td>
<td>$25.3</td>
<td>$35.00</td>
<td>$1.1M</td>
<td>2.2K</td>
<td>447</td>
</tr>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$28.1</td>
<td>$27.35</td>
<td>$27.35</td>
<td>$37.00</td>
<td>$913.5K</td>
<td>4.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$25.55</td>
<td>$25.35</td>
<td>$25.4</td>
<td>$35.00</td>
<td>$871.2K</td>
<td>2.2K</td>
<td>1.4K</td>
</tr>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$28.2</td>
<td>$27.3</td>
<td>$27.3</td>
<td>$37.00</td>
<td>$663.4K</td>
<td>4.4K</td>
<td>579</td>
</tr>
</tbody>
</table>

<h3>About Cleanspark</h3>
Cleanspark Inc is a bitcoin mining company. Through CleanSpark, Inc., and the Company's wholly owned subsidiaries, the company mines bitcoin. The company entered the bitcoin mining industry through its acquisition of ATL. Bitcoin mining is the sole reportable segment of the company.
Having examined the options trading patterns of Cleanspark, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Cleanspark</h3>
<ul>
<li>With a volume of 19,975,235, the price of CLSK is down -8.48% at $10.2. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 45 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cleanspark options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

CLSK

Cleanspark Options Trading: A Deep Dive into Market Sentiment

Investors with a lot of money to spend have taken a bullish stance on Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with APO, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 13 uncommon options trades for Apollo Global Management.
This isn't normal.
The overall sentiment of these big-money traders is split between 61% bullish and 30%, bearish.
Out of all of the special options we uncovered, 8 are puts, for a total amount of $281,262, and 5 are calls, for a total amount of $236,738.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $115.0 and $185.0 for Apollo Global Management, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Apollo Global Management options trades today is 1315.5 with a total volume of 2,992.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Apollo Global Management's big money trades within a strike price range of $115.0 to $185.0 over the last 30 days.
<h3>Apollo Global Management Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734981320_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>APO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.0</td>
<td>$2.85</td>
<td>$2.85</td>
<td>$180.00</td>
<td>$82.6K</td>
<td>1.2K</td>
<td align="right">336</td>
</tr>
<tr>
<td>APO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$12.2</td>
<td>$12.1</td>
<td>$12.2</td>
<td>$175.00</td>
<td>$64.6K</td>
<td>319</td>
<td align="right">649</td>
</tr>
<tr>
<td>APO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$59.3</td>
<td>$57.3</td>
<td>$58.7</td>
<td>$115.00</td>
<td>$58.7K</td>
<td>3.4K</td>
<td align="right">10</td>
</tr>
<tr>
<td>APO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/27/24</td>
<td>$10.1</td>
<td>$9.5</td>
<td>$9.5</td>
<td>$180.00</td>
<td>$38.0K</td>
<td>280</td>
<td align="right">40</td>
</tr>
<tr>
<td>APO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$7.6</td>
<td>$7.3</td>
<td>$7.4</td>
<td>$185.00</td>
<td>$35.5K</td>
<td>1.6K</td>
<td align="right">59</td>
</tr>
</tbody>
</table>

<h3>About Apollo Global Management</h3>
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Asset Management, Retirement Services, and Principal Investing. It generates maximum revenue from the Retirement Services segment.
After a thorough review of the options trading surrounding Apollo Global Management, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Apollo Global Management</h3>
<ul>
<li>Trading volume stands at 1,809,704, with APO's price up by 0.73%, positioned at $172.28.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 45 days.</li>
</ul>
<h3>What The Experts Say On Apollo Global Management</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $202.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from TD Cowen keeps a Buy rating on Apollo Global Management with a target price of $230. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Apollo Global Management, targeting a price of $197. 
&#x2A; Maintaining their stance, an analyst from BMO Capital continues to hold a Outperform rating for Apollo Global Management, targeting a price of $186. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Apollo Global Management with a target price of $202. 
&#x2A; An analyst from Keefe, Bruyette &amp; Woods has decided to maintain their Outperform rating on Apollo Global Management, which currently sits at a price target of $196. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Apollo Global Management, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Decoding Apollo Global Management's Options Activity: What's the Big Picture?

AVXL

Anavex Life Sciences shares are trading higher after the company announced better-than-expected Q4 financial results.

RKLB

Rocket Lab shares are trading higher. The company completed its 16th successful mission of 2024.

<a href="https://www.consumerfinance.gov/about-us/newsroom/cfpb-files-lawsuit-to-stop-illegal-kickback-scheme-to-steer-borrowers-to-rocket-mortgage/#:~:text=WASHINGTON%2C%20D.C.%20%E2%80%93%20Today%2C%20the,Rocket%20Mortgage%2C%20LLC%20for%20loans" title="https://www.consumerfinance.gov/about-us/newsroom/cfpb-files-lawsuit-to-stop-illegal-kickback-scheme-to-steer-borrowers-to-rocket-mortgage/#:~:text=WASHINGTON%2C%20D.C.%20%E2%80%93%20Today%2C%20the,Rocket%20Mortgage%2C%20LLC%20for%20loans">https://www.consumerfinance.gov/about-us/newsroom/cfpb-files-lawsuit-to-stop-illegal-kickback-scheme-to-steer-borrowers-to-rocket-mortgage/#:~:text=WASHINGTON%2C%20D.C.%20%E2%80%93%20Today%2C%20the,Rocket%20Mortgage%2C%20LLC%20for%20loans</a>.

CFPB Sues Rocket Homes And The Mitchell Group Over Kickback Scheme Steering Homebuyers To Rocket Mortgage; Alleges Suppression Of Down Payment Assistance Information And Seeks Consumer Redress And Civil Penalties

U.S. stocks traded mixed toward the end of trading, with the S&amp;P 500 gaining around 0.5% on Monday.
The Dow traded down 0.06% to 42,815.78 while the NASDAQ climbed 0.90% to 19,748.00. The S&amp;P 500 also rose, gaining, 0.54% to 5,962.84.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a>
Leading and Lagging Sectors Communication services shares jumped by 0.9% on Monday.
In trading on Friday, consumer staples shares fell by 1.2%.
Top Headline
U.S. building permits gained by 5.2% to an annualized rate of 1.493 million in November compared to initial estimates of 1.505 million.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Traws Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) shares shot up 144% to $12.23 after the company announced progress in the development of Tivoxavir Marboxi.</li>
<li>Shares of Reliance Global Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>)got a boost, surging 212% to $3.7401 after the company issued a year-end review of its operations, as well as a look to the future.</li>
<li>Rumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) shares were also up, gaining 86% to $13.36 after the company announced it has entered into a definitive agreement for a strategic investment of $775 million from Tether.</li>
</ul>
Equities Trading DOWN
<ul>
<li>iLearningEngines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AILE#NASDAQ">AILE</a>) shares dropped 74% to $0.2313 after the company announced it voluntarily filed for Chapter 11 Bankruptcy.</li>
<li>Shares of MGO Global, Inc. &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) were down 53% to $0.4479 after the company announced the pricing of upsized $6.0 million public offering.</li>
<li>Castellum, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTM#NYSE">CTM</a>) was down, falling 30% to $0.4216 after the company announced the pricing of a $3.6 million registered direct offering of 9.47 million shares at $0.38 per share.</li>
</ul>
Commodities In commodity news, oil traded down 0.1% to $69.37 while gold traded down 0.7% at $2,626.90.
Silver traded up 0.9% to $30.235 on Monday, while copper fell 0.4% to $4.0835.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 gained 0.14%, Germany's DAX fell 0.18% and France's CAC 40 fell 0.03%. Spain's IBEX 35 Index fell 0.28%, while London's FTSE 100 rose 0.22%.
Asia Pacific Markets
Asian markets closed mostly higher on Monday, with Japan's Nikkei 225 gaining 1.19%, Hong Kong's Hang Seng Index gaining 0.82%, China's Shanghai Composite Index declining 0.50% and India's BSE Sensex gaining 0.64%.
Economics
<ul>
<li>The Chicago Fed National Activity Index rose to -0.12 in November compared to a revised reading of -0.5 in October.</li>
<li>U.S. durable goods orders fell 1.1% month-over-month to $285.1 billion in November compared to a revised 0.8% gain in October and versus market estimates of a 0.4% decline.</li>
<li>U.S. building permits gained by 5.2% to an annualized rate of 1.493 million in November compared to initial estimates of 1.505 million.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42648003/how-to-earn-500-a-month-from-qualcomm-stock-2">How To Earn $500 A Month From Qualcomm Stock</a></li>
</ul>

Equities

Eurozone

Commodities

AILE

MGOL

RELI

TRAW

Gold Moves Lower, Rumble Shares Jump

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: A U.S. judge has blocked the proposed ...

Judge blocks Tapestry-Capri deal, Centene reports Q3 beat: Morning Buzz

H.C. Wainwright raised the firm's price target on Tyra Biosciences (TYRA) to $32 from $30 and keeps a Buy rating on the shares. The firm says TYRA-...

Tyra Biosciences price target raised to $32 from $30 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on Tyra Bioscience (TYRA – Research Report) today and set a price target of $32.00....

Buy Recommendation for Tyra Bioscience Based on Promising Clinical Data and Safety Profile of TYRA-300

Tyra Biosciences (TYRA) announced that the FDA cleared its Investigational New Drug application for Tyra-300 allowing the company to proceed with a...

Tyra Biosciences granted IND clearance from FDA for Phase 2 study of Tyra-300

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on TYRA stock, giving a Buy rating on October 29. Tyler Van Buren has given hi...

Tyra Bioscience's Promising Clinical Developments and Robust Pipeline Justify Buy Rating

Tyra Biosciences GAAP EPS of -$0.41 beats by $0.06

Oppenheimer analyst Matthew Biegler maintained a Buy rating on Tyra Bioscience (TYRA – Research Report) today and set a price target of $33.00. The...

Oppenheimer Sticks to Its Buy Rating for Tyra Bioscience (TYRA)

Tyra Bioscience, Inc ( ($TYRA) ) has released its Q3 earnings. Here is a breakdown of the information Tyra Bioscience, Inc presented to its investo...

Tyra Biosciences' Q3 2024: Clinical Progress and Financial Resilience

BofA lowered the firm's price target on Tyra Biosciences (TYRA) to $29 from $31 and keeps a Buy rating on the shares. Tyra had "an uneventful" Q3 u...

Tyra Biosciences price target lowered to $29 from $31 at BofA

The Take On Tyra Biosciences

AAPL

BBIO

BMRN

BYON

CPRI

DBRG

DECK

JOBY

MSFT

NYCB

PIPR

SNYNF

TMHC

TMUS

TSLA

TYRA

Earnings

Press Releases

Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights

Small Cap

TYRA Investors Have Opportunity to Join Tyra Biosciences, Inc. Securities Fraud Investigation with the Schall Law Firm

Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer

Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference

Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)

Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

Comments

Tyra Biosciences

Interés en corto

Tyra Biosciences (NASDAQ:TYRA) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL